(Q36706461)

English

A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients with Treatment Resistant Neovascular Age-Related Macular Degeneration following Switching to Treatment with Aflibercept

scientific article published on 6 March 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients with Treatment Resistant Neovascular Age-Related Macular Degeneration following Switching to Treatment with Aflibercept (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1 reference

based on heuristic

inferred from title

macular degeneration

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Oren Tomkins-Netzer

object named as

Oren Tomkins-Netzer

3

0 references

author name string

Sophie Seguin-Greenstein

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Sue Lightman

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

publication date

6 March 2016

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Journal of Ophthalmology

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

2016

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

4095852

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

copyright license

Creative Commons Attribution 4.0 International

1 January 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

Sex differences in outcomes of methadone maintenance treatment for opioid addiction: a systematic review protocol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month [...]

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

Measuring inconsistency in meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

The biology of VEGF and its receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

Age-Related Macular Degeneration and Blindness due to Neovascular Maculopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

30 September 2017

Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

28 June 2018

Retinal pigment epithelial cell loss assessed by fundus autofluorescence imaging in neovascular age-related macular degeneration.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

5 September 2018

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

5 September 2018

Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

5 September 2018

Random-effects model for meta-analysis of clinical trials: an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4799814

5 September 2018

Age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/27042342

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/27042342

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?

1 reference

https://pubmed.ncbi.nlm.nih.gov/27042342

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1155/2016/4095852

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36706461&oldid=1797180046"